GNT Pharma’s GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome
GNT Pharma today announced the Korea Animal and Plant Quarantine Agency (APQA) has approved the New Drug Application for GedaCure®, a chewable tablet of crisdesalazine, for the treatment of dogs with cognitive dysfunction syndrome (CDS) that suffer from disorientation, altered interactions with family, sleep-wake cycle disturbance, house soiling and changes in activity with aging.
GedaCure® is the world’s first multi-target neuroprotection drug for canine cognitive dysfunction syndrome. It is expected to improve the quality of life of aged dogs with CDS and their owners. GNT Pharma plans to launch GedaCure® in South Korea and will push ahead in earnest to advance globally for dogs and their family who suffer from CDS.
Like Alzheimer’s disease (AD), canine CDS is an age-related progressive neurodegenerative disease with a cognitive and behavioral deficit that is accompanied by beta amyloid precipitation, pathological tau, and neuronal death. The prevalence of senior dogs with CDS has been rapidly increasing with the extended lifespan, however, there is no cure for the disease.
Crisdesalazine prevents oxidative stress as a spin trapping agent and inflammation as an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), inducible enzymes essential for inflammatory PGE2 production. Crisdesalazine showed considerable effects in 3-D culture and animal models of Alzheimer’s disease in reducing neuronal death, tauopathy, and amyloid plaques to some extent which are pathological hallmarks of Alzheimer’s disease.
In a pilot clinical trial for canine CDS, all 6 companion dogs with CDS that received daily oral administration of 10 mg/kg crisdesalazine for 8 weeks showed remarkable symptomatic relief. Even in 4 weeks after administration of crisdesalazine, the dogs re-recognized and wagged their tails to their owners, slept well in the night, and revealed improved activity.
GNT Pharma conducted a double-blind, randomized, placebo-controlled phase III SMART trial of crisdesalazine for 48 companion dogs with CDS at 6 animal hospitals including Seoul National University Animal Hospital. All dogs were diagnosed as CDS according to canine cognitive dysfunction rating scale (CCDR score: 0-39 = normal, 40-49 = at risk, 50-80 = CDS). Baseline scores of CCDR before drug treatment were 61.7 ± 2.8 for the placebo group and 62.2 ± 2.3 for the crisdesalazine group. CCDR scores were 60.7 ± 2.7 and 65.0 ± 3.9 after 4-week and 8-week treatment with placebo. CCDR scores were reduced to 43.0 ± 2.9 and 42.1 ± 4.0 after 4-week and 8-week treatment with 5 mg/kg crisdesalazine, demonstrating significant beneficial effects of crisdesalazine vs placebo (p<0.0001). Similar beneficial effects were observed in companion dogs with CDS treated with 10 mg/kg crisdesalazine. Such beneficial effects lasted over at least 4 weeks after discontinuing 8-week treatment with crisdesalazine. Drug-related adverse events were not observed.
“Administration of crisdesalazine significantly and noticeably improved cognitive function and behavioral activity without causing adverse effects in dogs with CDS that participated in the SMART trial. With rapidly increasing population of aged dogs, CCDS has been one of therapeutic areas with the highest unmet medical need. In light of proven efficacy and safety, crisdesalazine is expected to improve the quality of life of aged dogs with CDS and their owners,” said Hwa-Young Youn, D.V.M. and Ph.D., Professor of Veterinary Medicine at Seoul National University, Principal Investigator of SMART trial.
“We are excited to receive a new drug approval for the treatment of old dogs with CDS. The novel dual antioxidant and anti-inflammatory action of crisdesalazine, which was shown to reduce amyloid plaque, tauopathy, and neurodegeneration in various cell culture and animal models, has the potential to revolutionize how we care for CDS,” said Byoung Joo Gwag, Ph.D., GNT Pharma’s President and CEO, Adjunct Professor of Biological Sciences at Yonsei University. “Crisdesalazine, the first multi-target drug proven and approved for CDS featuring brain pathology similar to AD, gives hope for better treatment of AD patients. We plan to initiate a pivotal clinical trial of crisdesalazine for patients with mild to moderate AD this year.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
COO, GNT Animal Health Care
Dr. Jinhwan Lee, +82-31-8005-9910 (EXT.217)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EAG Expands Medical Device Testing Services with New Laboratory7.5.2021 17:22:00 CEST | Press release
EAG Laboratories is expanding its medical device testing capabilities with a new 20,000 square-foot laboratory located in St. Louis, Mo. The new laboratory is a bespoke design to support the requirements of the medical device industry. It increases EAG’s analytical capabilities, allows for improved turnaround times and helps meet evolving requirements from the FDA as well as the European Union Medical Device Regulations (MDR). Specialty features of the laboratory include: A cleanroom designed for particle isolation and identification A dedicated medical device polymer analysis laboratory State-of the-art instrumentation to support biocompatitility testing of ISO 10993-18 programs for medical devices and combination products EAG scientists have been investigating and resolving product failures for more than half a century and have a deep understanding of materials and testing procedures. The medical device laboratory expansion allows EAG to leverage that knowledge and apply it toward su
SoftServe Wins Learning and Development Honor at 2021 ATD Excellence in Practice Awards7.5.2021 13:00:00 CEST | Press release
SoftServe, a leading digital authority and consulting company, won the Excellence in Practice Award in the ‘Learning and Development’ category in the 2021 Association for Talent Development (ATD) Excellence in Practice Awards. SoftServe was recognized for its corporate learning hub, SoftServe University, which focuses on learning and development opportunities for associates, including the design and delivery of training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210507005003/en/ Association for Talent Development logo. (Photo: Business Wire) “SoftServe is dedicated to creating a people-centric organization that allows associates to grow and develop professionally,” said Galyna Datsiv, AVP of Learning and Development at SoftServe. “Our corporate learning ecosystem within the integrated talent management framework enables us to reach SoftServe’s strategic business goals by ensuring associates are qualified and have the ex
Monument Assurance Belgium and Intégrale Reach Agreement for the Transfer of Intégrale's Entire Portfolio and Staff to MAB7.5.2021 12:26:00 CEST | Press release
Monument Assurance Belgium (“MAB”) and Intégrale have reached an agreement under which MAB will acquire the entire portfolio and all the staff of the insurance company Intégrale. This agreement follows a firm offer from MAB, which was considered by the provisional administrators appointed by the National Bank of Belgium (“NBB”) to be that which best meets the interests of Intégrale policyholders and staff. The transaction remains subject to the final approval of the NBB. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210507005270/en/ During the transition period, MAB and Intégrale will take all steps necessary to prepare for a seamless transfer for policyholders, brokers and staff. In the meantime, Intégrale's staff will continue to service policyholders and brokers as usual. In addition to the transfer of assets at the time of closing, MAB will offer an 18-month employment guarantee to all employees and, in addition, a 3-mo
The Metals Company Joins European Industry Alliances to Bolster Battery Supply Chain for the Clean Energy Transition7.5.2021 10:00:00 CEST | Press release
Today, The Metals Company (formerly DeepGreen), a developer of the world’s largest and highest-grade estimated source of battery metals, announced it has joined two of the European Union’s foremost industrial alliances—the European Raw Materials Alliance (ERMA) and the European Battery Alliance (EBA)—as the bloc advances its plans to become a global leader in the sustainable production of the batteries necessary to store clean energy and power electric vehicles (EVs). As a member of these industrial alliances, The Metals Company—which announced in March its plans to go public via a merger with the Sustainable Opportunities Acquisition Corporation (NYSE: SOAC)—brings a new, scalable source of battery metals to the table in the form of polymetallic nodules found unattached on the deep seafloor in the Pacific Ocean, which can help deliver upon their mandate for a diverse, reliable and responsible supply of critical minerals needed for low-carbon technologies. Under its Green Deal, the Eur
Morocco and UN Celebrate First-Ever International Argan Tree Day7.5.2021 08:30:00 CEST | Press release
Morocco and the United Nations will be marking the first-ever International Argan Tree Day on May 10th, 2021. The Argan tree, a tree specific to the Kingdom of Morocco, will thus be celebrated every year on May 10, as an intangible cultural heritage of humanity and ancestral source of sustainable development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005652/en/ February 22, 2021: The United Nations’ General Assembly adopted by consensus a resolution proclaiming May 10 of each year as the “International Argan Tree Day” (Photo: AETOSWire) The proclamation of the International Argan Tree Day was announced on March 3, 2021, when the UN General Assembly adopted by consensus a draft resolution initiated by Morocco and hailed by all United Nations’ member states. This milestone is a culmination of Morocco’s quest to mobilize the international community to protect and further develop the country’s Argan industry. It is al
Tigo Energy Demonstrates Optimization to Installers in Brazil with Stark Renováveis Installation7.5.2021 02:14:00 CEST | Press release
Tigo Energy, Inc., the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, announced today that Stark Renováveis has used the Tigo TS4-A-O to mitigate energy lost due to shade on their corporate headquarters in São José do Rio Preto, Brazil. Their confidence in Tigo’s solution drove the selection of the products for their own use. The Tigo solution gives installers and commercial system owners the freedom to choose their preferred inverters and panels along with the right features for optimized, monitored and PV safe systems. The Stark Renováveis team chose a rooftop PV system with 405 Wp modules organized in multiple strings and using GoodWeTM grid-tied inverters. The optimum placement of the modules was on a roof bordering a large construction wall which would ordinarily lead to shade and a degradation of the output. To mitigate the problem of energy lost due to shade, Tigo TS4-A-O optimizers were deployed to ensure the best possible system performance. "As
93 rd Vifor Pharma Group Annual General Meeting6.5.2021 18:00:00 CEST | Press release
Regulatory News: At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the coronavirus issued by the Swiss Federal Council, on the basis of Art. 8 of the new COVID-19 Act, shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 61.6% of the share capital was represented. Shareholder approvals Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd., as well as the consolidated Financial Statements of Vifor Pharma Group for 2020 by a large majority. The maximum possible 2022 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2020 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom